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Expression and purification of proteins   
Recombinant human β-cardiac myosin protein constructs – short subfragment 1 (sS1), short-tailed 
(2-hep), and long-tailed (25-hep) – were coexpressed with a FLAG-tagged human essential light 
chain (ELC) in mouse myoblast cells (C2C12) using adenoviral vectors. The sS1 constructs had 
either a C-terminal enhanced green fluorescent protein (“sS1-eGFP”) or a C-terminal eight-residue 
PDZ-binding peptide (“sS1-AC”). The sS1 constructs were purified with a FLAG affinity and ion-
exchange chromatography as previously described (1). The 2-hep and 25-hep constructs had both 
an eGFP and PDZ tag on their C-termini. For these longer constructs, human RLC was exchanged 
for the endogenous mouse RLC while bound to a FLAG resin, and then the myosin was purified as 
previously described (2).  
Actin was prepared as described previously (3) from bovine cardiac muscle (the sequences are 
identical between bovine and human actin). The actin was dialyzed in ATPase buffer (5 mM KCl, 1 
mM DTT, 3 mM MgCl2 and 10 mM imidazole) to form F-Actin for ATPase assays. 
  
Deadheading myosin 
Myosin protein used for unloaded motility experiments was further subjected to a ‘deadheading’ 
procedure to remove inactive heads. Myosin was mixed with 10x excess of unlabeled F-actin on 
ice for 5 min, followed by addition of 2 mM ATP for 3 min, then centrifuged at 95 krpm in a TLA-
100 rotor (Beckman Coulter) at 4 °C for 20 min. The supernatant was collected. We found that the 
P710R protein had more inactive heads than WT, as seen in a greater percentage of stuck filaments 
(5-15%) even after deadheading two times (Figure S2). In contrast, percent stuck filament was 0-
5% for WT sS1-AC with or without deadheading (Figure S2). Note, however, that these stuck 
filament percentages do not directly translate to the percentage of inactive heads; only a very small 
number of inactive heads (probably 1% or less) is needed to produce a much larger number of 
stuck filaments. For RTF motility experiments, we skipped deadheading because it did not 
substantially reduce percent stuck filaments, as 5-15% remained. This is likely because 
deadheading cannot remove 100% of completely or partially inactive heads. The fraction (on the 
order of 1% or less) of dysfunctional myosin molecules which remains after deadheading is 
expected to reduce ATPase by up to the same percentage. This percentage is clearly too small to 
explain the 39% reduction in ATPase activity of P710R sS1 that had been deadheaded (4). 
Although P710R 2 hep myosin was not deadheaded in the present paper, the percentage of dead 
heads is still likely too small to explain the 37% reduction in kcat of P710R 2-hep compared to WT 
2-hep. Thus, P710R’s measured reduced ATPase activity (at saturating actin concentrations) is 
interpreted as the mutant having reduced enzymatic activity even in “functional” molecules. Of 
course, one may view the P710R motor (or any other myosin with reduced ATPase activity) as not 
fully functional; one may also think of deadheads as an extension of “functional” motors with 
reduced activity. In these views, having less functional motors/more dead motors is part of the 
mutation’s effects, as reflected in the measured ATPase kcat’s. 
 
Single-molecule measurements of load-dependent detachment rates and step sizes with 
dual-beam optical trap 
The load-dependent detachment rates of WT and P710R sS1-eGFP molecules were measured in 
a dual-beam optical trap using the harmonic force spectroscopy (HFS) method previously 
described (5-7) with slight modifications. The sample chamber consisted of two double-sided tapes 
between a glass slide and a coverslip spin-coated with 1.6-um-diameter silica beads (Bang 





were done at 23 °C. The following solutions were flowed into the chamber sequentially, each with 
a couple minutes of incubation: 1. GFP antibody (Abcam ab1218) diluted to 1 nM in assay buffer 
(AB; 25 mM imidazole pH 7.5, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, and 10 mM DTT). 2. BSA 
diluted to 1 mg/mL in AB (ABBSA), to wash and block the surface. 3. Human β-cardiac myosin 
sS1-eGFP diluted to 10-50 nM in ABBSA, to bind all the GFP antibodies on the surface. 4. ABBSA, 
to wash. 5. A final solution consisting of 2 mM ATP, 0.3 nM TMR-phalloidin-labeled biotinylated 
actin (Cytoskeleton) filaments, an oxygen-scavenging system (0.4% glucose, 0.11 mg/mL glucose 
oxidase, and 0.018 mg/mL catalase), and 1-um-diameter NeutrAvidin-coated polystyrene beads 
(ThermoFisher) or 1-um-diameter streptavidin-coated polystyrene beads (Bang Laboratories) 
diluted in ABBSA. The chamber was sealed with vacuum grease and used for up to 2 hr.  
The two traps were calibrated using the power spectrum method with corrections for filters, aliasing, 
and surface effects (8), and their stiffnesses were 0.08-0.10 pN/nm in these experiments. After 
calibration, a “dumbbell” was made by stretching an actin filament between the two trapped beads 
(Figure S1A). While the stage oscillated at 200 Hz, the dumbbell was lowered near platform beads 
on the surface to test for binding to a potential myosin. Robust interactions with myosin were 
indicated by consistent, large, brief displacements of the trapped beads due to stronger association 
with the oscillating stage. We typically explored ~4-10 platform beads before robust interactions 
were observed, suggesting that the GFP antibody concentration used resulted in sufficiently low 
numbers of properly oriented molecules on the surface for single molecule conditions. Time traces 
were saved and automatically processed as previously described (5, 7). Briefly, events were 
selected based on a simultaneous increase in oscillation amplitude and decrease in phase between 
each bead and the stage (Figure S1B). The detachment rate at each force was determined by a 
maximum likelihood estimation from the durations of events within the force bin. The rates at 
different forces were then fitted to Eqn. 1 to obtain the two parameters k0 and . The data on multiple 
molecules presented in this paper are from multiple dumbbells in independent experiments from 
multiple days. Statistical significance of the difference in the weighted mean of these parameters 
between WT and P710R was determined using a two-tailed unequal variances t-test. 
The step sizes of myosins were determined from the same HFS data by adapting the ensemble 
averaging method (9) to HFS’s oscillatory data. For each molecule, position traces of all events 
were aligned at the start of binding, extended to the length of the longest event, and averaged 
(Figure S1C and D). Then the oscillations were removed by subtracting a fitted sine function (Figure 
S1D). The total step size for each molecule was taken as the difference between the initial position 
and the end position of the extended, averaged, sine-subtracted traces. Statistical significance of 
the difference in step size between WT and P710R was determined using a two-tailed unequal 
variances t-test. 
 
In vitro motility assays 
Motility measurements of WT and P710R sS1-AC used our previously described motility assay (10, 
11) with some modifications. Multi-channel flow chambers consisted of double-sided tapes 
between a glass slide and a coverslip pre-coated with a solution of 0.1% nitrocellulose/0.1% 
collodion in amyl acetate.  
For unloaded motility, the following solutions were flowed into the chamber sequentially: 1. SNAP-
PDZ18 (purified as described in Aksel et al. Cell Reports 2015 (10)) diluted to 3 μM in assay buffer 
(AB; 25 mM imidazole pH 7.5, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, and 10 mM DTT), incubated 
for 2 min. 2. BSA diluted to 1 mg/mL in AB (ABBSA), incubated for 2 min. 3. Human β-cardiac sS1-
AC diluted to ~200 nM in ABBSA, flowed twice with 2 min incubation each time. 4. ABBSA. 5. A 





oxygen-scavenging system (0.4% glucose, 0.11 mg/mL glucose oxidase, and 0.018 mg/mL 
catalase) in ABBSA. pH of the final solution was measured to be 7.5 at 23 °C. See Movies S1 and 
S2 for example motility measurements of WT and P710R, respectively. These conditions ensured 
that enough heads were on the surface such that velocities were detachment-limited. This is 
supported by the relationship between filament length and velocity in Figure S2 and by the absence 
of “wavy” filaments (in search of myosin heads) in Movies S1 and S2. The concentration of myosin 
we used was empirically optimized; using too high a concentration did not increase velocities further 
and resulted in excessive shredding of actin filaments into very short fragments.  
For RTF motility, a full pCa curve was generated by one slide with 6-7 channels. The following 
solutions were flowed into the channels sequentially: 1. SNAP-PDZ18 diluted to 3 μM in AB, 
incubated for 2 min. 2. ABBSA, incubated for 2 min. 3. Human β-cardiac sS1-AC diluted to 400-
600 nM in ABBSA, flowed twice with 2 min. incubation each time. 4. ABBSA. 5. TMR-phalloidin-
labeled actin filaments diluted to 10 nM in ABBSA, incubated for 1 min. 6. ABBSA. 7. A final solution 
consisting of 2 mM ATP, an oxygen-scavenging system (0.4% glucose, 0.11 mg/mL glucose 
oxidase, and 0.018 mg/mL catalase), 100 nM human troponin complex (expressed, purified, and 
complex formed as described in Sommese et al. PloS One 2013 (12)), 100 nM bovine cardiac 
tropomyosin (purified as described in Sommese et al. PloS One 2013 (12)), and varying amounts 
of CaCl2 (as calculated in (13)) in ABBSA. pH of the final solution was measured to be 7.5 at 23 
°C. Troponin and tropomyosin were added only in the final solution because we found that filaments 
were decorated with the regulatory proteins very quickly and certainly by the time the channels 
were imaged. 
The slide was then placed on a Nikon Ti-E inverted microscope with a 100x TIRF objective.  Images 
were taken for 30 sec at 2 Hz with 300 ms exposure on an Andor iXon+EMCCD camera. Three 
movies were recorded for each channel. The objective temperature was maintained at 23 +- 0.3 °C 
as closely as possible to minimize variations in velocities stemming from myosin’s high sensitivity 
to temperature. Movies of all channels on each slide were acquired as quickly as possible, within 
~15 min after flowing in the final buffer for the 6-7 channel slides. Despite our foregoing an ATP 
regeneration system, no slowing down of actin filaments was observed throughout imaging, nor 
any differences observed with or without an ATP regeneration system. 
Movies were processed by FAST (Fast Automated Spud Trekker) for filament tracking and velocity 
analysis (10) (Figure S2A and B). The following parameters were used in FAST: window size n = 
5, path length p = 10, percent tolerance pt = 80, and minimum velocity for stuck classification minv 
= 20 nm/s. Window size is the number of consecutive frames n over which frame-to-frame 
instantaneous velocities are averaged (let vn be this n-frame-averaged velocity). FAST outputs 
each vn rather than one velocity averaged over a filament’s entire path. Path length is the minimum 
number of frames in which a filament must be present in order for that filament’s vn’s to be included 
in the analysis. Percent tolerance pt is a parameter for further filtering out vn’s with non-smooth 
motion, as follows: vn’s are filtered out if their standard deviation (within the n frames) is greater 
than pt/100*vn. Minimum velocity for stuck classification minv is the minimum value (in nm/s) of the 
average of all vn’s for one filament for that filament to be classified as “stuck”, in which case all of 
the vn’s for that filament are then set to 0.  
“Mean velocity including stuck filaments (MVIS)” is simply the mean of all vn’s (including those that 
are 0) that satisfy the path length criteria. MVIS is not affected by the chosen percent tolerance 
value. All velocities reported in the main text are MVIS. Also note that MVIS is equivalent, up to a 
multiplicative factor, to the “percent time mobile” metric defined previously (10). “Mean velocity 





(MVELpt)” is the mean of vn > 0, which satisfy the path length criteria, and which satisfy the tolerance 
criteria (call these vn’s “filtered velocities”). Note that as the value of pt increases, MVELpt 
approaches MVEL. “Top5%” is the mean of the highest 5% values of “filtered velocities.” “Stuck 
percentage (%STUCK)” is the percentage of vn’s that are equal to 0.  
The lower minv value and higher pt value as used here are appropriate for analyzing loaded or RTF 
motility data in which filaments have stop-and-go movements. While a higher minv (80, as used in 
some previous publications) and lower pt (20 in some previous publications) are more appropriate 
for analysis of unloaded motility data (along with reporting Top5% (Figure S2C) or MVELpt 
velocities), we used the same set of FAST parameters to analyze all motility data reported in this 
paper so that values can be directly compared.  
For RTF motility, the Hill equation was fitted for each independent experiment producing MVIS 
values at 6-7 pCa concentrations (6-7 channels). Variation among the three movies taken for any 
particular channel was very minimal and smaller than variation between independent 
slides/experiments. Therefore, to capture the true experimental or biological variation, 4-5 
independent experiments (slides) were performed for both WT and P710R. Error bars on data 
points at each pCa value presented in Figure 2C represent s.e.m. of all independent experiments. 
Similarly, error bars on the fitted pCa50 and n values reported in Table 1 represent s.e.m. of the 
various fitted values from independent experiments.  
Statistical significances of the differences in velocities or fitted values between WT and P710R 
were determined using two-tailed unequal variances t-tests. 
 
Actin-activated ATPase assay 
NADH-coupled ATPases were used to compare the activity of the 2-hep and 25-hep constructs of 
WT and P710R -cardiac myosin as previously described (14). Briefly, actin was prepared as 
described in (3) and dialyzed 4x into ATPase reaction buffer without ATP: 5 mM KCl, 10 mM 
imidazole pH 7.5, 3 mM MgCl2, and 1 mM DTT. Gelsolin was prepared as previously described 
(15) and added to the actin at a final molar ratio of ~1:200. In a 96-well plate, actin was mixed with 
ATPase reaction buffer to achieve final concentrations of 1-100 μM, and myosin was added at a 
final concentration of 0.025 μM. To measure the basal rate without actin, myosin was added to 
ATPase reaction buffer at final concentrations of 0.075 – 0.125 μM. To initiate the reaction, a 5x 
coupling solution containing 100 U/mL lactate dehydrogenase (Sigma L1254), 500 U/mL pyruvate 
kinase (Lee Biosolutions 500-20), 2.5 mM phospho(enol) pyruvate (Sigma P0564), 10 mM ATP, 
and 2 mM NADH (Sigma N8129) was added at 1/5 the volume of the final reaction. The plate was 
shaken for 5 minutes at 23C before reading at 340 nm every 30 seconds for 25 minutes. A 
standard curve of ADP from 0 – 300 μM was created to convert the absorbance values to 
concentration of ADP produced.  
Data for P710R was collected from triplicate measurements of two independent protein 
preparations, where both P710R 2- and 25-hep were prepared in parallel with WT 2-hep as a 
control. Each independent protein preparation was fit to the Michaelis-Menten equation using the 
non-linear fit feature in PRISM, allowing for calculation of the maximum actin-activated ATPase 
activity rate (kcat) and Michaelis-Menten constant (KM) (Table S1 and Figure S3). To determine data 
reported in Table S1, we averaged these values from the two independent protein preparations, 
weighting based on the standard error of the fit. To determine p-values, a t-test was used. A 
representative example of this raw data is shown in Figure S3, where error bars represent the 
standard error of the triplicate measurements and the shaded area represents the 95% confidence 





preparation was normalized to the kcat of its same-day WT 2-hep control, then data from two protein 
preparations was combined and plotted on the same graph. Error bars represent standard error, 
and the shaded area represents the 95% confidence interval. WT 2-hep is not shown on the plot in 
Figure 3C for clarity.  
 
It is important to note that absolute values for kcat obtained over time vary significantly. We always, 
therefore, perform ATPase assays in parallel with both WT and mutant myosins on the same day, 
and we find that the differences between the WT and mutant values are very consistent. Thus, it is 
important to always use a same-day wild-type control to normalize such ATPase results. 
 
Mant-ATP single turnover assay 
Single turnover experiments were performed as previously described (16, 17), using WT and 
mutant versions of human ß-cardiac 2-hep and 25-hep. These experiments were performed in a 
96-well plate by mixing 200 nM myosin in a buffer (10 mM Tris pH 7.5, 4 mM MgCl2, 1 mM EDTA, 
1 mM DTT, 5 mM potassium acetate) with 2′-(or-3′)-O-(N-Methylanthraniloyl) adenosine 5′-
triphosphate (mant-ATP, Thermo Fischer Scientific) to a final concentration of 200-240 nM. ~10 s 
after mixing myosin and mantATP buffer, 2 mM ATP was added and the fluorescent signal (470 
nm Em/405 nm Ex) was measured every ~2 s for 16 min. The traces were normalized, plotted, and 
fit to a five parameter bi-exponential decay function to yield rates and amplitudes of fast (DRX) and 
slow (SRX) phases (Table S1). Statistical significance was determined by two-way ANOVA and 
specific differences assessed with Sidak’s multiple comparisons test. 
 
CRISPR/Cas9 based editing of hiPSCs 
The control human iPSC line (Stanford Cardiovascular Institute [SCVI-113]) was obtained from the 
Stanford CVI iPSC Biobank. These cells were acquired, reprogrammed and deidentified in 
accordance with approved IRB protocols and cultured in the appropriate media to maintain 
stemness.  The iPSCs were maintained in defined E8 media (Gibco) on tissue culture plates coated 
with Matrigel (Corning) diluted 1:100 in DMEM/F12 at 37°C in 5% CO2.  The P710R mutation was 
edited into these cells using a method that has been described previously (18, 19). We designed a 
guide RNA (GCTGCGCTGCAATGGTGTGCTGG) that was predicted to be highly specific to a site 
34 basepairs upstream of the desired mutation site and cloned it into the pSpCas9 (BB) 2A-GFP 
(PX458) plasmid. We also designed 500 basepair homology regions surrounding our cut site and 
including a C->G mutation at basepair 9699 to encode the P->R transition and a silent mutation to 
form a TTAA site at 9647-9650. These homology regions were cloned into an MV-Puro-TK plasmid 
surrounding a Puromycin resistance – TK selection cassette and both plasmids were introduced 
into the control iPSCs using Lipofectamine 3000. Puromycin was used to select for positively edited 
cells and then the Transposagen X reagent was used to excise the cassette leaving  “scarless” 
silent TTAA mutation and Ganciclovir was used to select for successfully repaired cells. 
Sequencing confirmed correct, single allele edits with no indels or other mutations on the second 
allele of MYH7 or on MYH6 (a close homologue in this region).  
 
Cardiomyocyte differentiation and culturing of hiPSCs 
Cells were differentiated into the cardiac lineage following a well-established protocol that relies on 
sequential activation and inhibition of the Wnt pathway. Specifically, we began differentiation when 
the cells reached ~75% confluence in RPMI media with B27 minus insulin supplement and 5 µM 
Chir-99021. After 24 hours, the media was replaced or supplemented with RPMI media with B27 
minus insulin supplement, and then at 48 hours, the media was replaced by RPMI media with B27 





differentiation, the media was replaced with RPMI media with B27 minus insulin supplement, and 
on the sixth day, the media was replaced with RPMI media with B27. Glucose starvation in glucose 
free RPMI with B27 was performed after the onset of beating for 4 days, and cells were replated 
before day 20 to allow for firm attachment to a fresh Matrigel coated plate. Cells were maintained 
in RPMI media with B27 for up to 60 days. Calcium transients were captured using a wide-field 
fluorescent camera on cells loaded  with Fluo4 dye after 30 minutes using a point electrode and 
1Hz pacing. Linear regions of interest approximately the length of 2-5 cells were chosen 
perpendicular to the direction of conduction at 4 different sites at least 2 mm apart. Transients were 
normalized to their baseline and the time to 90% of peak, time over 90%, and decay from 90% of 
peak to 5% above baseline times were measured and found to be not significantly different between 
control and mutant cells (Figure S8).  
 
Micropatterning hydrogels and substrates for microscopy 
Micropatterned hydrogels gels were created as previously described (20, 21). SU-8 
photolithography was used to create molds for stamps with rectangular features 10 µm deep with 
a 7:1 aspect ratio and an area of 2500 µm2. These single cell patterns were arranged in a 1 cm by 
1 cm grid, spaced to minimize the risk of mechanical interaction between adjacent cells. The area 
of these patterns was also larger than the median and 75 percentile of the cell spread area for both 
control and P710R cells (Fig. 6A), so it allowed for assessment of cell area with a spatial cue. 
Polydimethylsiloxane (PDMS) was mixed at a 9:1 by weight ratio of elastomeric base to primer and 
curing agent, mixed, degassed, and cured at 65°C for an hour. The PDMS stamps were coated in 
a 10:1 dilution of Matrigel in L15 media overnight at 4°C, rinsed in media and gently dried with 
Nitrogen. Stamps were then inverted and pressed onto cleaned and plasma-treated glass 
coverslips or Aclar film and weighted with a 50 g mass for at least 3 minutes to ensure even 
pressure and coverage.  
For creation of micropatterned hydrogels, a mixture of Acrylamide, Bisacrylamide, HEPES and 0.5 
µm fluorescent beads (Life Technologies, FluoSpheres) when used for traction force microscopy 
and polymerized with TEMED and 10% APS according to a formula which has been validated to 
produce gels of a stiffness of 10 kPa. This stiffness matches the physiologic stiffness of healthy 
myocardium near the beginning stages of disease.  
 
Traction force microscopy and calculation 
Single cell traction forces were assessed from single cells using algorithms described in our 
previous publications. We used both a Leica live cell imaging scope with a Prime 95 camera and a 
Nikon TiE microscope with an Andor Neo sCMOS camera. Cells were imaged in the bright-field to 
determine cell area and screen for beating, apparently single cells. Videos were then collected in 
the bright field and fluorescent channels to capture at least two full cardiac contraction cycles, at a 
minimum of 25 frames per second using a 40x 0.85NA or 20x air objective.   
Electrical field stimulation of 10V/cm at a frequency of 1 Hz was imposed with a carbon electrode 
throughout the acquisition of videos, and only cells that were able to keep up with 1 Hz pacing were 
included in further analysis. Our custom script and user interface in MATLAB allows for 
measurement of the cell outline and outputs the normalized displacements, total traction force, 
contraction time, moments, and integrated contraction impulse (force integrated over the time of 
contraction). The peak forces from these cells were not normally or log-normally distributed 
(according to Anderson-Darling, D’Agostino & Pearson, and Shapiro-Wilk tests), so statistical 





Immunostaining and electron microscopy 
At day 45 after differentiation, the cells were replated on tissue culture plastic, hydrogels or 
micropatterned aclar film and allowed to attach and grow for 4 or 7 days before fixing for further 
imaging. For immunostaining to determine cell size, cells were plated sparsely on a 48 well plate 
and allowed to attach for 4 days, and then fixed in 4% paraformaldehyde and permeabilized with 
0.1% triton. Cells were blocked in 5% BSA, stained with 1:200 cTnT primary antibody 
(Abcam:ab45932) and a 1:500 dilution of the 488 anti-rabbit antibody, stained with DAPI, and 
imaged on the Keyence microscope. Cell area was quantified with imageJ and Cell Profiler (22) 
and statistical differences in cell size were assessed with a non-parametric Mann-Whitney test in 
PRISM.  
For assessment of α- and β-myosin expression, cells were fixed and permeabilized in 4% PFA and 
0.05% triton for fifteen minutes, blocked in a goat serum solution for one hour, and incubated in 
1:50 β myosin mouse primary antibody, 1:100 α myosin rabbit primary antibody overnight at 4°C. 
Secondary antibodies Goat anti mouse 488 and Goat anti rabbit 647 were used to visualize and 
quantify the number of cells with clear sarcomeres comprised of α- and β-myosin.  
For electron microscopy, cells were grown on microcontact printed Aclar film for 1 week and the 
fixed with a mixture of  2% glutaraldehyde (EMS Ca# 16000) and 4% Formaldehyde (EMS Cat # 
15700) in 0.1M Sodium Cacodylate (EMS Cat# 12300) pH 7.4 for 1 hr.  The fixing solution was 
replaced with 1% Osmium tetroxide (EMS Cat# 19100) for 2 hours at room temperature, washed 
3x with ultra-filtered water, then stained in 1% Uranyl Acetate at RT for 2 hours. Samples were 
dehydrated in a series of ethanol washes (50%, 70%, 95%, 100%) for 30 min. each. The samples 
were transferred to Propylene Oxide (PO) and then infiltrated with Embed-812 resin (EMS 
Cat#14120) with PO at  1:2, 1:1 and 2:1 ratios for 2 hours and then placed in resin for 2 hours and 
placed in 65°C oven overnight. Thin sections (80 nm) were cut along a plane parallel to the 
patterned substrate plane of the cell (near the plane of attachment) using a Leica EM UC7 
Ultramicrotome and placed on 100 mesh coper grids (EMS). Samples were post-stained with 1.5% 
Uranyl Acetate in 50% Acetone for 30 seconds, then washed, dried, and then stained for 2 minutes 
in Sato’s lead cirtrate and imaged with a JEM-1400 transmission electron microscope (JEOL) at 
120 kV. Between 5 and 10 images were taken between 2500X and 3000X magnification with a on 
Gatan Orius 832 digital camera (Gatan, Pleasanton, CA) and sarcomere length and z-disk 
thickness was quantified in image J.    
 
Inhibitor study 
To clarify the effect of ERK and Akt, the cells were treated with either Akt inhibitor (Akti 1/2, Tocris: 
5µM) or and ERK inhibitor (SCH772984, SelleckChem: 1µM) every 3 days between day 26 and 
day 46 (a time frame over which hiPSC-CMs have been shown to increase in area). At day 46, the 
cells were replated sparsely at a density of 50 thousand cells per coverslip and on day 48 the cells 
were fixed and stained for β-myosin heavy chain and cardiac troponin T (Abcam:ab45932). The 
area of cells was quantified using Cell Profiler and the results from 2 batches of cells were combined 
and analyzed using Graphpad PRISM software with a 2-way ANOVA and the Kruskal-Wallis non-
parametric test for multiple comparisons.  
 
Assessment of protein transcription, expression and activation 
Batch-matched cell lysates were collected from nine separate differentiations between day 48 and 
66 of differentiation in either RIPA buffer supplemented with protease inhibitor, phosphatase 





blots, to measure both the activation of signaling proteins and the expression of myosin heavy 
chains, we used a 4-15% gradient gel (BIORAD) and separated at 150 V for 2 hours. Proteins were 
transferred to a nitrocellulose membrane at 80V for two hours on ice. These membranes were 
blocked in a 5% milk protein block solution in Tris buffered saline with 0.01% Tween (TBST), rinsed, 
and incubated overnight at 4 degrees in a 1:1000 solution of primary antibody in 2% BSA. After 
primary antibody incubation (pERK:Cell Signaling #9106S and pAkt: Cell Signaling #2965S), the 
gels were rinsed in TBST and incubated in 1:5000 secondary antibodies conjugated with HRP. 
After a final rinse, the gels were incubated for five minutes in Clarity ECL substrate (BIORAD), 
imaged on a chemidoc luminescent scanner, and band intensity was quantified in FIJI. After 
staining for the fluorescent protein, the membranes were stripped in a solution of 15 g glycine, 1 g 
SDS, 10 mL Tween 20 and distilled water (1L) and reblocked and reincubated in a 1:1000 dilution 
of primary for the total amount of protein (ERK:Cell Signaling 9102S and Akt: Cell Signaling 
#9272S). Many of these blots were also stained for α and β myosin antibodies that were developed 
by the Kraft lab and the Spudich lab. For each differentiation batch, the densitometry of 
measurements were normalized to the total protein, and then the sample from P710R cells were 
normalized to the control cells from that batch. Statistical significance was determined using a one 
sample t-test to test for a difference from 1.  
 
Computational modeling 
We used a previously validated model which incorporates discretized flux equations to describe 
transitions of myosin heads and thin filaments from inactive to active/bound states and predicts 
active and passive force (23, 24). This model also incorporates force-sensitive release of myosin 
heads from the thick filament and was modified to reflect the asymmetric load-dependent 
detachment rate (Figure S7). The fraction of binding sites in the active state was defined as Non. 
The regulation of the thin filament activation and flux between myosin states were calculated 
according to the method described in a previous publication (24). MOFF, MON, and MFG,i were defined 
as the fraction of myosin in the OFF state (equivalent to SRX), the ON state (available but 
unbound), and force generating states with i=1-41 different displacements (x) between the binding 
site and the zero load position of the myosin head. The range of potential positions of myosin heads 
relative to the no-load position (xi) range from -10 to 10 nm with a bin size of 0.5 nm. A series of 
flux equations (J1, J2, J3, and J4) describe the transitions between these myosin states, and J1, J2, 
and J3 were defined as previously described (24): 
 
𝐽1 = 𝑘−SRX(1 + 𝑘force ∗ 𝐹Total)𝑀OFF Eqn. S1 
𝐽2 = 𝑘+SRX ∗ 𝑀on Eqn. S2 
𝐽3(𝑥) = 𝑘A ∗ 𝑒
−𝑘cb𝑥
2
2𝐾𝐵𝑇 ∗ 𝑀on(𝑁on − 𝑁bound) Eqn. S3 
J1 represents the flux of myosin heads from MOFF to MON and is proportional to the fraction of heads 
in the SRX state. Based on previous modeling results and studies of the SRX state in muscle fibers 
and myofibrils, we assumed that the rate would be increased by increasing force in the muscle and 
so included a coefficient of force-sensitivity (kforce) with units of N-1 m2. J2 represents the flux of 
myosin heads from MON to MOFF and is proportional to the fraction of heads in the ON state. J3 
represents the flux of myosin heads from MON to MFG,i and is proportional to MON as well as the 





attachment rate of myosin to available actin (kA). The Gaussian term reflects the probability of a 
myosin head with spring constant kcb being stretched to length x by thermal energy. kcb is the 
stiffness of the crossbridge spring and has units of N m-1. KB is the Boltzmann’s constant (1.38 x 
10-23 J K-1) and T is the temperature (set to 310 K). We modified the final flux equation J4 describing 
bound myosins exiting the attached state to reflect the exponential load dependence observed in 
our single molecule measurements.  
𝐽4(𝑥) = 𝑘0 ∗ 𝑒
−𝑘cb𝑥𝛿
𝐾𝐵𝑇 ∗ 𝑀FG,i(𝑥i)  
if |xi| < 8 nm, and  
𝐽4(𝑥) = (𝑘0 ∗ 𝑒
−𝑘cb𝑥𝛿
𝐾𝐵𝑇 + (|𝑥i| − 8) ∗ 𝑝max⁡) ∗ 𝑀FG,i(𝑥i) Eqn. S4 
when |xi| > 8 nm. 
k0 and  were defined from HFS measurements and pmax is the maximum parameter rate (set to 
5000 s-1). The overall rate of detachment increases towards pmax as the displacement of the myosin 
head relative to its baseline position extends beyond 8 nm (Figure S8A) based on reported 
averages for powerstroke ranges and a natural limit for myosin head extension (25). Adding the 
muscle force (N m-2) normalized by the number of myosin heads (1.2 x 1016 m-2) into the calculation 
of detachment rate caused only a very small change in the overall fit (less than 10% increase in 
mean normalized deviation). The highest expected contribution of this normalized force at peak for 
these cells is less than half than the force of the individual cross bridge springs, so it was not 
included in these calculations. These flux expression were used to solve a series of differential 
equations at each time step (1 ms intervals) to calculate the fraction of myosin in each state and 
resultant total force, as previously described (24).  
𝐹total =⁡𝐹active + 𝐹passive⁡ Eqn. S5 
𝐹active =⁡𝑁0𝑘cb ∑ 𝑀FG,i(𝑥i + 𝑥ps)
𝑛
𝑖=1  Eqn. S6 
𝐹passive = 𝑘p(𝐿 − 𝐿0) Eqn. S7 
The total force is comprised of active and passive force components. The active force depends on 
the powerstroke step size (xps), cross bridge stiffness (kcb) and on the number of myosin heads in 
a hypothetical cardiac half-sarcomere with a cross-sectional area of 1 m2 (N0). N0 was set to 1.2x 
1016 for these simulations. This estimation was derived from the assumptions that there are ~100 
myosin heads oriented towards actin per half thick filament (26), the half filaments have a spatial 
density of 4 x 1014 m-2 (27), and the myofibrils in cell occupy ~30% of the cell space (by our 
observation in electron microscopy images). Multiplying these three numbers together (100 x 4 x 
1014 x 0.3) gives an estimate of 1.2 x 1016 for the average myosin head density, but variation in the 





variability observed in the cells (Figure 7C).  The passive force was determined based on a linear 
passive stiffness term (kp), defined as 10 N m-2 nm-1, and the change in length from the baseline 
length (L0) of 880 nm (to match the sarcomere lengths we measured in these cells). It also included 
a series stiffness of 100 N m-2 nm-1 that has previously been shown to improve model fit to 
relaxation dynamics (28). This parameter accounts for serial compliance of the cell and substrate 
and was adjusted to predict shortening of the sarcomeres (Figure S9E) within the range of cell 
shortening we measured for these cells (2-3%) and the percent sarcomere shortening measured 
in previous studies of hiPSC-CMs with MYH7 mutations (29).  
To implement the modified model in the context of this project, we first incorporated the rates and 
parameters directly measured in our molecular characterization of the effects of the P710R 
mutation (k0, , and step size [xps]). We used previously reported actin activated ATPase 
measurements using WT and P710R sS1 constructs to define kA (4). The values were calculated 
from the previously published forward attachment rate of myosin (kA) multiplied by the Kapp to 
account for changes in actin affinity and the fractional (unitless) description of actin availability in 
this model. This scaling of kA transforms it to units of s-1 (compared with the reported units of s-1 
M-1  (4)). Finally, after calculating this rate constant (kA) from previously reported values, we 
divided by the integral of the gaussian term (which depends on kcb) to describe the density of flux 
at each segment of the available range of binding, making the final units calculated within the model 
(s-1  nm-1) consistent with rate constants previously reported using this model (24)). We also 
calculated the force at baseline (Fbaseline) as the total force after 500 ms of equilibration (before 
initiation of the calcium transient) for each simulation.  
We normalized our measured Ca2+ traces and scaled them between pCa 6.17 and 6.72 according 
to the reported calibrated values from the previously published model simulations (24) as the input 
protocol for these simulations (Figure S9A). The rate constant for thin filament deactivation (koff) 
was limited to 100-200 s-1 and the k+SRX rate constant was held unchanged between control and 
mutant myosin simulations at 200 s-1, consistent with the previous publication of this model (24). 
We initially set kon, kcoop, kforce, kcb to previously reported values from cardiac tissue twitch and 
optimized these parameters to find the best fit of Ftotal – Fbaseline to our representative traces of cell 
forces normalized by cross sectional area. kon is a rate constant (M-1 s-1) that determines the rate 
of thin filament activation proportional to the concentration of Ca2+.  kcoop is a unitless term that 
describes the interactions between regulatory units on the thin filament that contribute to 
myofilament cooperativity. These interactions further suppress thin filament activation at low Ca2+ 
concentrations while augmenting activation at higher Ca2+ concentrations. k-SRX for control was set 
to 20 s-1, based on measurements of the SRX percentage in cell ranging from ~60 to 90% in hiPSC-
CMs (29). After defining a parameter set that fit the WT curve, a specific optimization of the value 
for k-SRX for the P710R myosin was performed by initially setting the value of k-SRX to that of the WT 
myosin (20 s-1) and allowed to varied between 0 and a 20 fold increase over WT. We also compared 
the fit to the data after optimizing the relative change in both k-SRX and kforce or just k+SRX (Figure 
S9), but found less than 1% improvement in the mean normalized deviation (error term defined in 
previous description of the model (24)). We calculated confidence limits for these parameter fits by 
varying the parameter until the mean normalized deviation exceeded the best fit value by more 
than 5%, as previously described (24, 30). We also performed sensitivity analysis to determine the 
effect of each parameter on the active force and the %SRX at peak contraction (Figure S10). While 
holding the rest of the parameters constant at the best fit values, we varied one parameter to 0.1, 







Figure S1. Analysis of harmonic force spectroscopy (HFS) optical trap data to determine the 
step size of a single myosin molecule. A. Schematic of HFS in the dual-beam optical trap. 
Myosin (orange) sits on top of a platform bead on a stage that oscillates sinusoidally with position 
xstage. The positions of the trapped beads x1 and x2 are recorded. Upon binding of myosin to the 
actin (blue) stretched across the two trapped beads (“actin dumbbell”), myosin undergoes the 
power stroke, moving actin (blue arrow). B. The stage position xstage, positions of trapped beads x1 
and x2, amplitudes of x1 and x2, and phases of x1 and x2 relative to the stage position are shown 
around one example binding event. Upon myosin’s attachment to actin, the amplitude of the 
sinusoidal oscillations in x1 and x2 increases while the phase decreases because the actin dumbbell 
is now strongly coupled to the oscillating stage. The detected binding event is highlighted in color. 
C. Time traces of three example events before (gray) and during (black) binding. D. All bound traces 
from one molecule (hundreds of binding events) are start-aligned, extended, and averaged (dark 
gray curve with large amplitude of oscillation). A fitted sine function is subtracted from the averaged 
trace, revealing the change in actin dumbbell position due to myosin binding alone (black). Myosin’s 








Figure S2. Analysis of the actin-sliding velocities of P710R and WT sS1-AC in the unloaded 
motility assay. A. and B. Fast Automated Spud Trekker (FAST) analysis of data from an example 
motility experiment using WT (A) (Movie S1) and P710R (B) (Movie S2) sS1-AC. The FAST 
parameters used for this paper were window size n = 5, path length p = 10, percent tolerance pt = 





left scatter plot represents the n-frame averaged velocity value of a filament plotted against the 
filament length; thus, depending on the total number of movie frames in which a filament is present, 
multiple data points belong to that filament. Blue data points represent the n-frame averaged 
velocities that pass a “tolerance (pt)” criteria to filter out velocities with large fluctuations (see 
methods for exact criteria). The “Top5%” dashed line represents the mean of the highest 5% values 
of the tolerance-filtered velocities. The distribution of filament lengths is shown in the bottom left 
histogram, with the mean shown as the vertical line. The distribution of n-frame averaged velocities 
(with and without tolerance filtering) are shown in the upper right histograms. The mean of the 
filtered velocities (MVELpt) and the mean of the unfiltered velocities (MVEL) are shown as the 
horizontal line in each histogram. For a filament whose velocity averaged over its entire path is less 
than minv, its n-frame averaged velocities are all set to 0. %STUCK is the percentage of velocities 
that have value 0. These 0 velocities are not shown on the FAST plots (other than via the value 
%STUCK) but are taken into consideration by the metric “Mean velocity including stuck (MVIS)”, 
the metric used in the main figure in this paper (see methods). Values of Top5% and MVELpt 
resulting from tolerance filtering at different pt values are given in the bottom right plots. C. and D. 
Top 5% velocities (C) and %STUCK (D) of all WT and P710R motility experiments. Each data point 







Figure S3. ATPase for WT and P710R 2-hep and P710R 25-hep myosin. Representative traces 
(3 replicates per concentration), one of two protein preps which gave similar results (and are 
presented as normalized results in Figure 3).  Rates are calculated per myosin head (2 heads per 
construct for 2-hep and 25-hep constructs). Error bars represent s.e.m of measurements, and the 
shaded area shows the standard error of the fit. 
  




























Figure S4: Gene editing confirmation of heterogeneous editing at site of interest. Excerpts 









Figure S5: Full analysis of effects of Akt and ERK inhibition. Isogenic control cells were grown 
in parallel and treated with Akti and ERK inhibitors (Akti 1/2 and SCH772984) for 21 days (media 
change every 3 days). Scale bar represents 50 μm. The differences in size were quantified using 
Cell Profiler and analysis using a 2-way ANOVA and non-parametric test correcting for multiple 
comparisons. * signifies p < 0.5, **** signifies p < 0.0001. 
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Figure S6: Quantification of pERK, pAkt and α and β myosin in cell population. (A) Western 
blots were performed on N=6 batches of hiPSC-CMs to determine the phosphorylation of ERK and 
Akt and confirm that further normalization using the loading control (GAPDH) did not change the 





























































































































































































































































































































































































expression of each myosin type (quantified by densitometry and normalization against GAPDH) 
was further normalized to the protein expression level in the isogenic control cells for that 
differentiation batch. The mean relative expression was compared to 1 to test for significance (* 
indicates p < 0.5). (C) Relative transcription was also measured using qPCR. (D) Representative 
immunostaining images of unpatterned cells stained for α- and β-MHC and quantification of the 
number of cells from 3 differentiation batches expressing α- and β-MHC were not significantly 







Figure S7: Myosin transition rates for WT and P710R myosin influence crossbridge 
distribution. (A) Transition rates after parameter estimation reflect the increase in k-SRX and 
decreased force sensitivity with the P710R mutation. (B) Analysis of the distributions of crossbridge 
lengths (x) during the contraction cycle show a more rightward shift (towards higher resistive loads) 
for the WT, with a more centered distribution for the P710R. (C) Attached, force generating (as a 
fraction of total) myosin over the time course of activation. (D) Calculated duty ratio as fraction of 






Figure S8: Measurement of Calcium Transients in P710R cells. (A) Representative transients 
from measurements of calcium in monolayers of hiPSC-CM. The time to peak was measured as 
the time between when the normalized signal crossed 5% of the range until it reached a threshold 
of 90% of the peak, and the time at peak was the time above a 90% threshold. Time to relax was 
quantified as the time to fall from 90% of peak to 5%, and the relative Fluorescence was the 
magnitude of peak fluorescence normalized to the baseline intensity. There were no significant 







Figure S9: Optimization and additional modeling predictions. (A) Calcium transients measured 
in cellular monolayers were used as an input for the model. (B) After fitting parameters including 
kforce and kcb to pedict the experimental control trace, optimization was used to find the best fit for 
k-SRX, starting at the initial value of k-SRX for controls. (C) After fitting, the model predicted altered 
actin availability deriving from the changes in myosin kinetics. (D) The fitting technique was able to 
optimize the value of k-SRX for the best fit to the combined force data. Similar optimizations allowing 
both k-SRX and kforce or only k+SRX to change followed a similar trajectory reducing error and ended 
with predictions similary to k+SRX. (E) and (F) the predictions for sarcomere length change and 







Figure S10: Sensitivity analysis of individual parameter’s effects on outputs. Each parameter 
was varied from 0.1 to 10 times its initial value to show that parameters relative effects on peak 







Figure S11: Additional myofibril distributions in micropatterned cells. There is both variable 
density of myofibrils and variable structural maturity across cells when measured in (A) 











Table S1. kcat and KM presented as fit (± SE of fit). kfast, kslow, and fast fraction are presented as 
mean ± SEM, and the text in blue is data previously published by Adhikari et al. in 2019 and adapted 
from ref. 16, which is licensed under CC BY 4.0  
 kcat, s-1 KM, μM kfast, s-1 kslow. s-1 Fast fraction 














P710R 2-hep  3.7 ± 0.3  4.5 ± 1.2  
0.04  




 ± 0.02  
P710R 25-
hep 













Table S2: Parameters used in model after optimization. Red parameter labels signify 
parameters which were different between control and mutant simulations, and asterisks signify the 
parameters which were optimized to find a best fit to the experimental force (with red asterisks 
denoting fitting of mutant parameter separately 
Parameter (units) Control P710R Confidence limits for fits 
k-SRX (s-1) 20 258*  [215-292] 
kforce (N-1 m2) 6E-5 6E-5  
k+SRX (s-1) 200 200  
kA (s-1) 656.7 701.5  
k0 (s-1) 104 87  
δ (nm) 1.39 0.3  
xps (nm) 5.2 1.9  
kcb (N m-1) 0.00063* 0.00063* [0.00058-0.00064] 
kon (M-1 s-1) 3.2E7* 3.2E7* [3.02E7 - 4.0E7] 
koff (s-1) 200 200  
kcoop (unitless) 7* 7* [6.8-8.1] 
kp (N m-2 nm-1) 10 10  





















0.037 711 589 88.4 90.2 
Optimized fit 
P710R 
0.316 3193 998 27.8 40.4 
Only k-SRX  0.25 770 2101 25.8 39.2 
Only kA 0.039 338 606 88.2 90.1 
Only xps 0.036 644 473 88.7 90.2 
Only kdet  0.038 263 563 88.3 90.2 
Not k-SRX  0.039 2821 447 88.4 90.2 
Not kA 0.290 8660 947 29.1 40.7 
Not xps 0.347 3872 2041 22.6 39.0 








Movie M1 (separate file). Actin motility of WT ꞵ-cardiac myosin sS1-AC. Playback speed 3.5x. 
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